TriangleFOR PATIENTS · SOURCE READING
Treatment of Recurrent Soft Tissue Sarcoma
Source: Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 2, 2023 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, see Treatment Option Overview. To learn about the cancer stages, see Stages of Soft Tissue Sarcoma.
Source links and citations
Treatment of recurrent soft tissue sarcoma may include the following:
Surgery (wide local excision) with or without radiation therapy.
Source links and citations
Surgery (amputation; rarely done).
Source links and citations
Surgery to remove cancer that has recurred in the lungs.
Targeted therapy with a tyrosine kinase inhibitor (pazopanib or imatinib).
Source links and citations
Chemotherapy.
Source links and citations
A clinical trial of an immune checkpoint inhibitor (pembrolizumab, nivolumab, or ipilimumab).
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice